All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

This NIHR Collection brings together major studies on the prevention and treatment of childhood eczema. It finds that many common interventions are not effective. Studies also explore the support that ...

Organon (OGN) announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA cream, 1% once ...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...

Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...

Skin reactions can be alarming, especially when they appear suddenly. Many people struggle to tell the difference between ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup ...

A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...

Kenvue (KVUE) will share new clinical data demonstrating how its brands are leveraging the latest science to shape the future of the Skin ...

Eli Lilly (LLY) stock in focus as eczema therapy Ebglyss lead to complete skin clearance in 50% of subjects in a long-term ...

The 2025 American Academy of Dermatology Annual Meeting will take place March 7-11 in Orlando. The meeting will feature nearly 300 educational sessions with more than 1,700 speakers discussing the ...